Astellas To Explore IBS Endpoints Before Advancing Ramosetron Into Phase III

Japanese pharma hopes its novel 5-HT3 antagonist will enter Phase III trials in 2008 after completion of an FDA-requested study of endpoints used in irritable bowel syndrome trials.